These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18361309)

  • 1. Special considerations in the design, conduct and analysis of prophylaxis trials.
    Radhakrishna S
    Indian J Tuberc; 2008 Jan; 55(1):34-41. PubMed ID: 18361309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Defining an ethics for preventive trials].
    Chippaux JP
    Bull Soc Pathol Exot; 2008 Apr; 101(2):85-9. PubMed ID: 18543698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and analysis of trials with rare outcomes: examples from trials in herpes transmission and influenza prophylaxis.
    Keene O
    Contemp Clin Trials; 2005 Jun; 26(3):311-22. PubMed ID: 15911465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Planning a cluster randomized controlled trial: methodological issues.
    Christie J; O'Halloran P; Stevenson M
    Nurs Res; 2009; 58(2):128-34. PubMed ID: 19289934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the validity of clinical trials.
    Akobeng AK
    J Pediatr Gastroenterol Nutr; 2008 Sep; 47(3):277-82. PubMed ID: 18728521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials and statistical analyses: what should dermatologists look for in a report?
    Alosh M; Fritsch K; Soukup M; Wilkin J
    Dermatol Ther; 2009; 22(3):199-203. PubMed ID: 19453343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
    Vaucher P
    Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The scientific basis of clinical trials: statistical aspects.
    Gehan EA
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2587-90. PubMed ID: 9815661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A primer on the design, conduct, and interpretation of clinical trials.
    Appel LJ
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1360-7. PubMed ID: 17699370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthening gynecologic cancer prevention studies.
    Hill DA
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):639-50, vii. PubMed ID: 18061861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpreting HIV clinical trials.
    Glesby MJ
    AIDS Clin Care; 1999 Jul; 11(7):58-9. PubMed ID: 11366435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method.
    Pritchett YL; Tamura R
    Pharm Stat; 2008; 7(3):170-8. PubMed ID: 17538942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy research in times of patient preference].
    Lüdtke R
    Z Arztl Fortbild Qualitatssich; 2005; 99(4-5):279-84. PubMed ID: 16044785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive misconception: its nature, presence, and ethical implications for research.
    Simon AE; Wu AW; Lavori PW; Sugarman J
    Am J Prev Med; 2007 May; 32(5):370-4. PubMed ID: 17478261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Statistical notes. Randomized controlled clinical trials of both superiority and non-inferiority: critical considerations].
    Marubini E; Rebora P; Reina G
    Ital Heart J Suppl; 2005 Jun; 6(6):361-4. PubMed ID: 16013427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of risk of bias in randomized clinical trials in surgery.
    Gurusamy KS; Gluud C; Nikolova D; Davidson BR
    Br J Surg; 2009 Apr; 96(4):342-9. PubMed ID: 19283747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
    Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
    J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Methodological and statistical aspects of equivalence and non inferiority trials].
    Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
    Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.